|
23 Companies |
|
30 Products |
|
30 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
425 News |
|
| 123456789» |
- | carvedilol / Generic mfg.
Phase classification: Carvedilol PAH A Pilot Study of Efficacy and Safety (clinicaltrials.gov) - Jul 11, 2019
P1, N=5, Terminated, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Phase classification: P2 --> P1
- ||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Adult Congenital Heart Disease Registry (QuERI) (clinicaltrials.gov) - Jan 23, 2019
P=N/A, N=217, Completed, Sponsor: Actelion
Phase classification: P2 --> P1 Active, not recruiting --> Completed | N=800 --> 217 | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018
- ||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: PILGRIM: Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 27, 2018
P=N/A, N=73, Completed, Sponsor: Gachon University Gil Medical Center
Active, not recruiting --> Completed | N=800 --> 217 | Trial completion date: Dec 2018 --> May 2018 | Trial primary completion date: Dec 2018 --> May 2018 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=48 --> 73 | Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Jun 2016 --> Dec 2018
- | diltiazem / Generic mfg.
Enrollment change: Efficacy Study of Cardizem in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Nov 20, 2018
P=N/A, N=0, Withdrawn, Sponsor: University of South Florida
Recruiting --> Completed | Phase classification: P4 --> PN/A | N=48 --> 73 | Trial completion date: Dec 2016 --> Dec 2018 | Trial primary completion date: Jun 2016 --> Dec 2018 N=40 --> 0
- ||||||| Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion, Trial completion date: Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument (clinicaltrials.gov) - Oct 31, 2018
P3b, N=284, Completed, Sponsor: Actelion
N=40 --> 0 Active, not recruiting --> Completed | Trial completion date: Jul 2016 --> Nov 2015
- | Trial completion, Enrollment change: The Role of Endothelin in Pulmonary Hypertension (clinicaltrials.gov) - Oct 24, 2018
P2, N=38, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | Trial completion date: Jul 2016 --> Nov 2015 Active, not recruiting --> Completed | N=80 --> 38
- | Enrollment change, Trial termination: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Sep 26, 2018
P=N/A, N=33, Terminated, Sponsor: Imperial College London
Active, not recruiting --> Completed | N=80 --> 38 N=93 --> 33 | Recruiting --> Terminated; numbers recruited to show adequate association but not primary outcome
- || Trial completion date, Trial primary completion date: Adult Congenital Heart Disease Registry (QuERI) (clinicaltrials.gov) - Aug 24, 2018
P=N/A, N=800, Active, not recruiting, Sponsor: Actelion
N=93 --> 33 | Recruiting --> Terminated; numbers recruited to show adequate association but not primary outcome Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- Opsumit (macitentan) / Nippon Shinyaku, J&J
Trial completion date: SYMPHONYext: Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument (clinicaltrials.gov) - Aug 22, 2018
P3b, N=4, Terminated, Sponsor: Actelion
Trial completion date: Sep 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Trial completion date: Jul 2016 --> Nov 2017
- ||| Trial completion: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=797, Completed, Sponsor: Actelion
Trial completion date: Jul 2016 --> Nov 2017 Active, not recruiting --> Completed
- | Trial completion, Trial completion date, Trial primary completion date: Inhaled Nitrite in Subjects With Pulmonary Hypertension (clinicaltrials.gov) - Jul 25, 2018
P2, N=48, Completed, Sponsor: Schmidhofer, Mark, MD
Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Dec 2018 --> Oct 2017
- | tezosentan (ACT-050089) / Roche
Phase classification: Tezosentan in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jul 9, 2018
P2a, N=3, Terminated, Sponsor: Idorsia Pharmaceuticals Ltd.
Recruiting --> Completed | Trial completion date: Dec 2018 --> Oct 2017 | Trial primary completion date: Dec 2018 --> Oct 2017 Phase classification: P2 --> P2a
- ||| Tracleer (bosentan) / J&J, Roche
Trial completion, Combination therapy: First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 12, 2018
P=N/A, N=12, Completed, Sponsor: University of Calgary
Phase classification: P2 --> P2a Recruiting --> Completed
- | carvedilol / Generic mfg.
Trial termination: Carvedilol PAH A Pilot Study of Efficacy and Safety (clinicaltrials.gov) - Apr 27, 2018
P2, N=5, Terminated, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed Completed --> Terminated; Low enrollment
- | Trial completion, Trial completion date: RVMET: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Apr 13, 2018
P=N/A, N=20, Completed, Sponsor: Ottawa Heart Institute Research Corporation
Completed --> Terminated; Low enrollment Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Phase classification, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - Apr 9, 2018
P, N=13, Completed, Sponsor: Bayer
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Jul 2017 Phase classification: P=N/A --> P
- | Trial completion, Trial completion date, Heterogeneity, Compliance: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging (clinicaltrials.gov) - Mar 23, 2018
P=N/A, N=16, Completed, Sponsor: Massachusetts General Hospital
Phase classification: P=N/A --> P Recruiting --> Completed | Trial completion date: Sep 2017 --> Mar 2018
- || Trial completion date, Trial primary completion date: PAH QuERI Ext: Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (clinicaltrials.gov) - Mar 12, 2018
P=N/A, N=797, Active, not recruiting, Sponsor: Actelion
Recruiting --> Completed | Trial completion date: Sep 2017 --> Mar 2018 Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Jan 2018 --> Jun 2018
- | Enrollment change: Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=20, Completed, Sponsor: Laval University
Trial completion date: Mar 2018 --> Jun 2018 | Trial primary completion date: Jan 2018 --> Jun 2018 N=40 --> 20
- Tracleer (bosentan) / J&J, Roche
Enrollment change, Trial withdrawal: Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan (clinicaltrials.gov) - Mar 6, 2018
P4, N=0, Withdrawn, Sponsor: Rajan Saggar
N=40 --> 20 N=50 --> 0 | Recruiting --> Withdrawn
- sildenafil / Generic mfg.
Enrollment change, Trial withdrawal: Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil (clinicaltrials.gov) - Mar 6, 2018
P4, N=0, Withdrawn, Sponsor: Rajan Saggar
N=50 --> 0 | Recruiting --> Withdrawn N=50 --> 0 | Recruiting --> Withdrawn
- | Trial primary completion date: Inhaled Nitrite in Subjects With Pulmonary Hypertension (clinicaltrials.gov) - Jan 25, 2018
P2, N=50, Recruiting, Sponsor: Schmidhofer, Mark, MD
N=50 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Dec 2017 --> Dec 2018
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: Comparative PK PD Study in PAH Patients (Fox vs. I-Neb) (clinicaltrials.gov) - Oct 23, 2017
P1/2, N=27, Completed, Sponsor: Bayer
Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- ||| treprostinil / Generic mfg.
Trial completion: PKRemodulin: Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=51, Completed, Sponsor: Jeffrey A. Feinstein
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial primary completion date: Inhaled Nitrite in Subjects With Pulmonary Hypertension (clinicaltrials.gov) - Oct 3, 2017
P2, N=50, Recruiting, Sponsor: Schmidhofer, Mark, MD
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> Dec 2017
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Phase classification: SPHERA: Efficacy of Ventavis Used in Real-life Setting. (clinicaltrials.gov) - Sep 21, 2017
P=N/A, N=52, Completed, Sponsor: Bayer
Trial primary completion date: May 2017 --> Dec 2017 Phase classification: P4 --> P=N/A
- |||| ambrisentan / Generic mfg.
Trial primary completion date, Combination therapy: AMBITION: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 13, 2017
P3, N=610, Completed, Sponsor: GlaxoSmithKline
Phase classification: P4 --> P=N/A Trial primary completion date: Apr 2014 --> Jul 2014
- | Trial completion, Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=629, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Trial completion: Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years (clinicaltrials.gov) - Aug 11, 2017
P2, N=40, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014 Active, not recruiting --> Completed
- | Trial primary completion date: DYSLIM: Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=199, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Mar 2014
- | Trial completion: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Jul 17, 2017
P=N/A, N=25, Completed, Sponsor: Medical University of Graz
Trial primary completion date: Jan 2015 --> Mar 2014 Active, not recruiting --> Completed
- | Trial completion: Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=55, Completed, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment change, Trial primary completion date: NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up (clinicaltrials.gov) - Jul 7, 2017
P=N/A, N=40, Completed, Sponsor: NordicInfu Care AB
Recruiting --> Completed N=25 --> 40 | Trial primary completion date: Sep 2014 --> Dec 2016
- | Trial completion, Enrollment change: Vascular Subphenotypes of Lung Disease in HIV & COPD (clinicaltrials.gov) - Jun 21, 2017
P=N/A, N=30, Completed, Sponsor: University of Pittsburgh
N=25 --> 40 | Trial primary completion date: Sep 2014 --> Dec 2016 Recruiting --> Completed | N=140 --> 30
- | Trial withdrawal, Trial primary completion date: Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 9, 2017
P1/2, N=0, Withdrawn, Sponsor: University of Illinois at Chicago
Recruiting --> Completed | N=140 --> 30 Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2015 --> Dec 2018
- carvedilol / Generic mfg.
Trial completion, Enrollment change: Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension (clinicaltrials.gov) - Jun 8, 2017
P1/2, N=10, Completed, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2015 --> Dec 2018 Recruiting --> Completed | N=15 --> 10
- || treprostinil / Generic mfg.
Trial primary completion date: PKRemodulin: Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - May 11, 2017
P=N/A, N=51, Active, not recruiting, Sponsor: Jeffrey A. Feinstein
Recruiting --> Completed | N=15 --> 10 Trial primary completion date: Dec 2016 --> Aug 2017
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - May 4, 2017
P=N/A, N=13, Completed, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> Aug 2017 Active, not recruiting --> Completed
- | Trial primary completion date, Heterogeneity, Compliance: Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=15, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Trial primary completion date: Jan 2017 --> Sep 2017
- Tyvaso (treprostinil) / United Therapeutics Corp
Trial completion, Enrollment change: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication (clinicaltrials.gov) - Mar 15, 2017
P4, N=9, Completed, Sponsor: Los Angeles Biomedical Research Institute
Trial primary completion date: Jan 2017 --> Sep 2017 Active, not recruiting --> Completed | N=21 --> 9
- | Orenitram (treprostinil diethanolamine oral) / United Therapeutics Corp
Enrollment closed: Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years (clinicaltrials.gov) - Feb 20, 2017
P2, N=40, Active, not recruiting, Sponsor: United Therapeutics
Active, not recruiting --> Completed | N=21 --> 9 Recruiting --> Active, not recruiting
- | Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Compliance: Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=17, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion: IBUKI: Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (clinicaltrials.gov) - Feb 8, 2017
P3, N=27, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: RVMET: Rt Ventricular Substrate Metabolism as a Predictor of Rt Heart Failure in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: Ottawa Heart Institute Research Corporation
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial primary completion date, Compliance: Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=13, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2016 --> Jul 2016
- ||||||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial completion: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Jan 23, 2017
P3, N=61, Completed, Sponsor: Bayer
Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- |||| selonsertib (GS-4997) / Gilead
Trial completion: ARROW: Selonsertib in Adults With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Dec 23, 2016
P2, N=151, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Inhaled Nitrite in Subjects With Pulmonary Hypertension (clinicaltrials.gov) - Dec 12, 2016
P2, N=50, Recruiting, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Trial primary completion date: Oct 2016 --> May 2017
- |||| Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: RESPITE: Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor (clinicaltrials.gov) - Dec 8, 2016
P3, N=61, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2016 --> May 2017 Trial primary completion date: Dec 2017 --> Dec 2016
- |||| Ventavis (iloprost) / Bayer, J&J, University of Copenhagen
Trial completion, Phase classification: SPHERA: Efficacy of Ventavis Used in Real-life Setting. (clinicaltrials.gov) - Nov 28, 2016
P4, N=52, Completed, Sponsor: Bayer
Trial primary completion date: Dec 2017 --> Dec 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P4